---
title: Find safe dose for Parkinson
nct_id: NCT06189170
phase: EARLY_PHASE1
status: RECRUITING
sponsor: Kariya Pharmaceuticals
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06189170"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06189170"
last_fetched: "2026-05-10T14:02:15.416Z"
source: "Parkinson's Pathways (curated)"
---
# Find safe dose for Parkinson

**Goal (in five words):** Find safe dose for Parkinson

**Official Title:** A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.

**Trial ID:** [NCT06189170](https://clinicaltrials.gov/study/NCT06189170)

## Key Facts

- **Phase:** EARLY_PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Kariya Pharmaceuticals
- **Target Enrollment:** 88 participants
- **Start Date:** 2024-08-01
- **Completion Date:** 2025-12-31
- **Conditions:** Safety Issues, Tolerance
- **Interventions:** KP405, Placebo
- **Intervention Types:** DRUG

## Summary For Families

The trial is aiming to establish whether KP405 is safe and well tolerated, and to find appropriate dose ranges before any larger Parkinson's studies. Participants receive single and then multiple escalating doses of KP405 or placebo, so researchers can track how the drug is handled by the body, what side effects appear, and whether it is tolerated alongside usual Parkinson's care such as levodopa. Adults aged 18 to 80 are being recruited, including healthy volunteers and people with Parkinson's who meet UK Brain Bank criteria, while people with other significant neurological or unstable medical conditions are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, cardiac Holter monitoring and clinical laboratory evaluations.
* Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria.

Exclusion Criteria:

* Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including \[but not limited to\], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder), excluding Parkinson's disease.
* Clinically significant, as judged by the Investigator, neurologic disorder (other than Parkinson's disease) including history of stroke or transient ischaemic attack within 12 months of Screening, cognitive impairment, seizure within 5 years of Screening or head trauma with loss of consciousness within 6 months of Screening.
```

## Locations (1)

- MAC, Manchester, United Kingdom _(53.4809, -2.2374)_
  - Ezanul Wahab — (CONTACT)

## Central Contacts

- Ian Laquian, MBA — (CONTACT) — 5170029 — Ian.laquian@kariyapharma.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06189170*  
*HTML version: https://parkinsonspathways.com/trial/NCT06189170*  
*Source data: https://clinicaltrials.gov/study/NCT06189170*